Partnerships

iCAALL

Hundreds of millions of people in the world suffer from allergies, and it is estimated that 300 million have asthma. Inadequate or improper diagnosis and treatment of these chronic diseases and of immunodeficiency disorders results in lost productivity and substantial medical and socioeconomic burdens throughout the world.

Recognizing a lack of consensus-driven information and general recommendations, four of the most influential allergy/immunology professional organizations have joined forces to launch the International Collaboration in Asthma, Allergy and Immunology (iCAALL).

Participating in iCAALL are the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma & Immunology (ACAAI), the European Academy of Allergy and Clinical Immunology (EAACI) and the World Allergy Organization (WAO).
iCAALL is designed to collect and disseminate consensus-driven information about allergies, asthma and immunological diseases. Communicating this knowledge can positively impact diagnosis and treatment, as well as cost containment and policy decisions.

Most recent publications
The importance of allergic disease in public health: an iCAALL statement (2018)
International consesnsus (ICON) on: clinical consequences of mite hypersensitivity, a global problem (2017)
ICON: chronic rhinosinusitis (2014)
International consesus on drug allergy (2014)

GA²LEN

GA²LEN is a Network of Excellence of the leading European clinical and research facilities in the field of allergology and asthma, associated with EAACI and the organisation representing European patients with allergies and asthma (EFA). Started under the European Union Sixth Framework Programme for Research, GA²LEN has become a model project in Europe.

Its objectives in Allergy and Asthma are to:

- Enhance the quality and relevance of research and address all aspects of the disease
- Create a permanent and durable structure that will maximize the scientific contribution of Europe to this area
- Accelerate the application of research results to clinical practice, patients' needs and policy development
- Promote training and integration between the public and private sectors

For more information please visit: www.ga2len.net

BioMed Alliance

EAACI joined the Alliance for Biomedical Research in Europe in March 2014 and attended the most recent General Assembly in Brussels on 11 April 2014.

The Alliance for Biomedical Research in Europe is a unique initiative representing 21 leading research-oriented medical societies that include more than 400,000 researchers across Europe. The BioMed Alliance is committed through its acrions to promote excellence in European biomedical research and innovation with the goal of improving the health and well-being of all European citizens.

For more information please visit: www.biomedeurope.org

European Chronic Disease Alliance (ECDA)
EAACI became a member of the European Chronic Disease Alliance (ECDA) in February 2014 and attended the first EU Summit on Chronic Diseases from 3 - 4 April.
The ECDA represents an unprecedented alliance of 11 not-for-profit European organisations representing over 100,000 health professionals and patients. They have joined forces to put the case for immediate political action to reverse the alarming rise in chronic diseases which affects more than a third of the population of Europe - over 100 million citizens.

For more information please visit: alliancechronicdiseases.org/

European Medicines Agendy (EMA)

EAACI became eligible to be involved in the European Medical Agency's (EMA) activities in April 2014 and was added to the list of healthcare professional's organisations which is published on the agency's website.

The link to the list of eligible organisations is intended for patients and healthcare professionals who may have a question related to a specific disease/illness and who could then contact the relevant organisation(s) who work with the EMA.

For more information please visit: www.ema.europa.eu/en

Last updated 23 September 2019

Thank you!

Thank you!